US6534693B2
Expired / Lapsed
US
⏱️ 0.0 years remaining
Surgically implanted devices having reduced scar tissue formation
Assignee: IPXMEDICAL LLC
•
Filing: 2001-01-31
•
Granted: 2003-03-18
•
Expires: 2021-01-31
Abstract
Abstract This invention is an anti-proliferative drug placed onto or within a sterile sheet or mesh that is designed to be placed between internal body tissues to prevent the formation of post-operative adhesions, which adhesions are really scar tissue formation. This mesh or gauze onto or into which the drug is placed may be either a permanent implant or it may be biodegradable. By impregnating an existing product such as the Johnson & Johnson SURGICEL™ absorbable hemostat gauze-like sheet with an anti-proliferative drug such as Rapamycin or Taxol, the biodegradable, drug impregnated mesh would act as a barrier to cell proliferation and hence be a deterrent to the formation of adhesions. Another embodiment of this invention is an anti-proliferative drug attached to a bandage that is placed onto a cut in the skin to decrease scar tissue formation. Still another embodiment of the invention is an anti-proliferative drug that is attached to a surgical suture or coated onto a surgical staple both of which are used for connecting human tissues. The suture or staple then being more capable for decreasing cellular proliferation where the suture or staple material passes through the human tissue.
Inventors
- 👤 Robert E. Fischell
- 👤 David R. Fischell
- 👤 Tim A. Fischell
- 👤 Scott J. S. Fischell
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 12:21
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/50; A61L27/54; A61B; A61B17/00; A61B17/04; A61B17/06; A61B17/06166; A61L15/00; A61L15/16; A61L15/42; A61L15/44; A61L31/00; A61L31/14; A61L31/16; A61B17/064; A61B2017/00831; A61F; A61F2/00; A61F2/0063; A61F13/00; A61F2013/00361; A61F2013/00365; A61F2013/00451; A61L2300/00; A61L2300/40; A61L2300/416; A61L2300/424; A61L2300/60; A61L2300/602; A61L2300/604; A61L2300/62; A61L2300/622; A61L2300/626
Claims Analysis
Total Claims: 30
Claim 1
Independent Claim
66 words
A sheet of material adapted for implantation between tissues of a human body, the sheet of material including an attached anti-proliferative drug, the anti-proliferative drug being designed to reduce the generation of scar tissue, the anti-proliferative drug being selected from the group consisting of Rapamycin, taclolimus (FK506), and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.
Claim 2
Dependent Claim
66 words
A sheet of material adapted for implantation between tissues of a human body, the sheet of material including an attached anti-proliferative drug, the anti-proliferative drug being designed to reduce the generation of scar tissue, the anti-proliferative drug being selected from the group consisting of Rapamycin, taclolimus (FK506), and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.
Claim 3
Dependent Claim
12 words
The apparatus of claim 1 wherein the sheet of material is biodegradable.
Claim 4
Dependent Claim
17 words
The apparatus of claim 1 wherein the sheet of material is in the form of a mesh.
Claim 5
Dependent Claim
54 words
In combination, including an anti-proliferative drug attached to a bandage for placement over a cut on the skin of a human subject, the anti-proliferative drug being selected from the group consisting of taclolimus (FK506), Rapamycin and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.
Claim 6
Dependent Claim
54 words
In combination, including an anti-proliferative drug attached to a bandage for placement over a cut on the skin of a human subject, the anti-proliferative drug being selected from the group consisting of taclolimus (FK506), Rapamycin and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.
Claim 7
Dependent Claim
62 words
In combination, including an anti-proliferative drug attached to a surgical suture, the suture being adapted to connect human tissue that is separated by a surgical procedure on a human subject, the anti-proliferative drug being selected from the group consisting of taclolimus (FK506), Rapamycin and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.
Claim 8
Dependent Claim
62 words
In combination, including an anti-proliferative drug attached to a surgical suture, the suture being adapted to connect human tissue that is separated by a surgical procedure on a human subject, the anti-proliferative drug being selected from the group consisting of taclolimus (FK506), Rapamycin and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.
Claim 9
Dependent Claim
77 words
In combination, including an anti-proliferative drug attached to a mesh having a generally cylindrical shape for introduction into a generally cylindrical cavity of the human body to decrease scar tissue formation in that generally cylindrical cavity after a surgical procedure on that generally cylindrical cavity, the anti-proliferative drug being selected from the group consisting of taclolimus (FK506), Rapamycin and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.
Claim 10
Dependent Claim
77 words
In combination, including an anti-proliferative drug attached to a mesh having a generally cylindrical shape for introduction into a generally cylindrical cavity of the human body to decrease scar tissue formation in that generally cylindrical cavity after a surgical procedure on that generally cylindrical cavity, the anti-proliferative drug being selected from the group consisting of taclolimus (FK506), Rapamycin and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.
Claim 11
Dependent Claim
14 words
The combination of claim 6 wherein the generally cylindrical cavity is a human nostril.
Claim 12
Independent Claim
67 words
A device to reduce scar tissue formation within the eye of a human subject after a retinal attachment procedure, including a buckle designed to be placed onto the eye, the buckle including an attached anti-proliferative, the anti-proliferative drug being selected from the group consisting of taclolimus (FK506), Rapamycin and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.
Claim 13
Independent Claim
67 words
A device to reduce scar tissue formation within the eye of a human subject after a retinal attachment procedure, including a buckle designed to be placed onto the eye, the buckle including an attached anti-proliferative, the anti-proliferative drug being selected from the group consisting of taclolimus (FK506), Rapamycin and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.
Claim 14
Dependent Claim
85 words
An implantable device adapted for surgical implantation within a space within a human body at a location that is external to any vessel of that human body, at least part of the device including an attached anti-proliferative drug, the action of the anti-proliferative drug being a reduction in the generation of scar tissue, the anti-proliferative drug being selected from the group consisting of Rapamycin, taclolimus (FK506), and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.
Claim 15
Dependent Claim
85 words
An implantable device adapted for surgical implantation within a space within a human body at a location that is external to any vessel of that human body, at least part of the device including an attached anti-proliferative drug, the action of the anti-proliferative drug being a reduction in the generation of scar tissue, the anti-proliferative drug being selected from the group consisting of Rapamycin, taclolimus (FK506), and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.
Claim 16
Dependent Claim
17 words
The device of claim 9 wherein the device is in the form of a prosthetic breast implant.
Claim 17
Dependent Claim
17 words
The device of claim 9 wherein the device is in the form of an arterio-venus fistula shunt.
Claim 18
Independent Claim
85 words
A method for improving the outcome of a surgical procedure, the method being the release into a human subject on whom the surgical procedure has been performed of an anti-proliferative agent in combination with at least one other drug selected from the group consisting of antiseptic agents, anti-biotic agents and analgesic agents, and the anti-proliferative agent being selected from the group consisting of Rapamycin, taclolimus (FK506), and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamy-cin, 32-demethoxy, 2-desmethyl and proline.
Claim 19
Independent Claim
85 words
A method for improving the outcome of a surgical procedure, the method being the release into a human subject on whom the surgical procedure has been performed of an anti-proliferative agent in combination with at least one other drug selected from the group consisting of antiseptic agents, anti-biotic agents and analgesic agents, and the anti-proliferative agent being selected from the group consisting of Rapamycin, taclolimus (FK506), and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamy-cin, 32-demethoxy, 2-desmethyl and proline.
Claim 20
Dependent Claim
20 words
The method of claim 12 wherein the anti-proliferative agent is used in an ointment that is applied to the skin.
Claim 21
Dependent Claim
31 words
The method of claim 12 wherein the anti-proliferative agent is attached to a mesh that is adapted to be placed within the human subject in whom the surgical procedure was performed.
Claim 22
Dependent Claim
15 words
The method of claim 12 wherein the anti-proliferative agent is attached to a breast implant.
Claim 23
Dependent Claim
14 words
The method of claim 12 wherein the anti-proliferative agent is attached to a suture.
Claim 24
Dependent Claim
12 words
The method of claim 12 wherein the anti-proliferative agent is released systemically.
Claim 25
Independent Claim
94 words
A method for decreasing the formation of scar tissue after a surgical procedure, the method comprising the following steps: a) attaching an anti-proliferative drug onto a sheet of material designed to be placed onto or into a human subject; the anti-proliferative drug being selected from the group consisting of Rapamycin, taclolimus (FK506), and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline; and b) placing the mesh with the attached anti-proliferative drug onto or into a human subject during or after completing a surgical procedure.
Claim 26
Independent Claim
94 words
A method for decreasing the formation of scar tissue after a surgical procedure, the method comprising the following steps: a) attaching an anti-proliferative drug onto a sheet of material designed to be placed onto or into a human subject; the anti-proliferative drug being selected from the group consisting of Rapamycin, taclolimus (FK506), and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline; and b) placing the mesh with the attached anti-proliferative drug onto or into a human subject during or after completing a surgical procedure.
Claim 27
Dependent Claim
27 words
The method of claim 18 further including the step of systemic application of at least one anti-proliferative drug at least one day prior to the surgical procedure.
Claim 28
Dependent Claim
29 words
The method of claim 18 further including the step of a continuing systemic application of at least one anti-proliferative drug for at least one day after the surgical procedure.
Claim 29
Dependent Claim
54 words
In combination, an anti-proliferative drug attached to a breast implant, the breast implant being designed to provide breast enlargement for a human female subject, the anti-proliferative drug being selected from the group that includes taclolimus (FK506), Rapamycin and the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.
Claim 30
Dependent Claim
54 words
In combination, an anti-proliferative drug attached to a breast implant, the breast implant being designed to provide breast enlargement for a human female subject, the anti-proliferative drug being selected from the group that includes taclolimus (FK506), Rapamycin and the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.
References Cited (Backward Citations)
USRE33375E
Cited
US4865031A
Cited
US4895566A
Cited
US4863457A
Cited
US4952403A
Cited
US5843156A
Cited
US5540931A
Cited
US6117425A
Cited
US5387589A
Cited
US5708002A
Cited
US5151413A
Cited
US5516781A
Cited
US6221099B1
Cited
US5693607A
Cited
US5981568A
Cited
US5552162A
Cited
US5624893A
Cited
US5912253A
Cited
US6063396A
Cited
US5618553A
Cited
US5756673A
Cited
US5496832A
Cited
US6200985B1
Cited
US6124273A
Cited
US5798334A
Cited
US5912224A
Cited
US6143037A
Cited
US5795286A
Cited
US6015815A
Cited
US6273908B1
Cited
US6060474A
Cited
WO2001087372A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2006-03-17 | 2006-09-16 | 2007-03-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2010-03-17 | 2010-09-16 | 2011-03-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2014-03-17 | 2014-09-16 | 2015-03-18 | $7700.00 | Window Closed / Lapsed |